NEW YORK--(BUSINESS WIRE)--Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national shareholder and consumer rights litigation firm, announces the commencement of an investigation into Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG”) related to potential violations of federal securities laws. If you are a CBMG shareholder, you are encouraged to contact Scott+Scott for additional information.
CBMG (NASDAQ:CBMG) is a biomedicine company that develops treatments for cancerous and degenerative diseases in Greater China. CBMG focuses on developing and marketing cell-based therapies to treat serious chronic and degenerative diseases.
On April 7, 2015, Seeking Alpha published a report on CBMG, which asserts that: (i) CBMG has achieved an unsustainable valuation with paid stock promotion; (ii) CBMG’s “CAR-T” technology has experienced patient deaths and is worthless; (iii) CBMG’s founders face multiple allegations of dishonesty and are responsible for an alleged illegal offshore stem cell clinic; and (iv) CBMG has multiple accounting and financial integrity issues. On this news, shares of CBMG fell sharply during intraday trading on April 7, 2015.
What You Can Do
If you are a CBMG shareholder and you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Joseph Halloran at (800) 404-7770 or (646) 582-0121 or at or email@example.com.
About Scott+Scott, Attorneys at Law, LLP
Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide.